AlphAIAlphAI — Financial news for AI agents
investing.com$TNGX

Tango Therapeutics earnings on deck after ESMO data readout

Tango Therapeutics (TNGX) reports Q3 earnings, with focus on its lead cancer drug, vopimetostat. Analysts expect a 35-cent loss per share, no revenue. Shares fell 18% post-data update, but 12/13 analysts rate it buy with $47.09 avg. target. Investors watch for Phase 3 trial timeline and cash burn updates.

Original reporting
investing.com
Published Nov 9, 2026, 3:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 3:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$TNGX
Bearish
high confidence
Mentioned
$TNGX
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$TNGXBearishMed
01

Why it matters

The earnings release and updated trial data introduce new risk factors, notably a lower response rate and cash‑burn concerns, which may drive the stock lower in the short term.

02

Market read

The article provides the first public disclosure of Q3 earnings and fresh Phase 1/2 data, making it a primary source of material information for traders.

03

What to watch

Potential partnership or licensing deals for vopimetostat could provide non‑dilutive capital.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Tango Therapeutics is a clinical‑stage biotech focused on PRMT5 inhibition for MTAP‑deleted cancers. It has no revenue and relies on cash reserves to fund its pipeline.

Company-level read

Ticker impact

$TNGXBearishHigh confidence
Context

Tango Therapeutics (TNGX) is reporting Q3 results and new Phase 1/2 data from its lead drug vopimetostat, which caused an 18% share drop.

Expected impact

downward pressure as the market prices in weaker efficacy data and ongoing cash‑burn concerns

Evidence & confidence

The article provides the first disclosure of the Q3 earnings and fresh trial data, both material to valuation.

Market effects

Sector

The data may temper enthusiasm for PRMT5 inhibitors across biotech, affecting peers developing similar epigenetic therapies.

Regional

Limited to US‑listed biotech sector; no broader market effect.

Global

Modest, as the trial is early‑stage and impacts a niche oncology segment.

Counterpoint

What could challenge this read

If the Phase 3 trial proceeds as planned, the long‑term upside could outweigh short‑term data setbacks.

Key entities

  • company
    Tango Therapeutics Inc.

    Clinical‑stage biotech developing vopimetostat.

  • company
    Revolution Medicines

    Partner providing daraxonrasib for the combination trial.

Read at source← All news

Also covered by

1 outlet

Related articles

$TNGXMedAI 8/10

Tango Therapeutics Reports Q3 2026 Net Loss of $68.4 Million

Tango Therapeutics reported a Q3 2026 net loss of $68.4M, up from a $15.9M profit a year earlier, due to higher expenses and zero collaboration revenue. Cash reserves totaled $977.5M. The company shared promising Phase 1/2 results for vopimetostat combined with daraxonrasib in pancreatic cancer, with an 82% response rate and 88% nine-month survival rate. Tango plans to initiate a Phase 3 trial in 2027 and focus on PRMT5-targeted therapies.

tradingview.com
$TNGXMedAI 8/10

Tango Therapeutics 3Q 2026: Revenue $0, EPS ($0.39) — 10-Q Summary

Tango Therapeutics reported no revenue in 3Q 2026, down from $53.8M a year earlier, with a net loss of $68.39M. R&D and G&A expenses rose, partially offset by higher interest income. Clinical trials for vopimetostat combinations showed promising results. The company plans a global trial in 2027 and will focus on PRMT5 therapies, reducing its workforce by 14%.

tradingview.com
$TNGXHighAI 9/10

Tango Therapeutics Reports Third Quarter 2026 Financial Results

Tango Therapeutics, Inc. (TNGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights Promising Phase 1/2 data from combination study of vopimetostat plus daraxonrasib presented at 2026 ESMO Congress demonstrated 82% objective response rate (ORR) and 88% 9-month progre

SEC EDGAR 8-K
$TNGXMedAI 8/10

Wedbush raises Tango Therapeutics stock price target on trial data

Wedbush raised Tango Therapeutics' (TNGX) price target to $45 from $39, citing positive trial data for vopimetostat in combination with RayzeBio's inhibitors. The stock has surged 271% over the past year, trading at $24.21 with a $4.06B market cap. Analysts see potential upside of 61% to their consensus target. Other analysts have also raised targets, with H.C. Wainwright at $68 and Stifel at $55.

investing.com
$TNGXMedAI 8/10

Stifel raises Tango Therapeutics stock price target on trial data

Stifel raised its price target for Tango Therapeutics (TNGX) to $55 from $40, maintaining a Buy rating. The company's shares have surged 271% over the past year. Stifel increased its peak sales estimate to $7.1 billion, citing trial data. Tango Therapeutics announced workforce reductions and plans to focus on key therapies, with updates expected in 2027. Other analysts have also raised their price targets, with varying opinions on the stock's valuation.

investing.com